Guangxi Zhou

TL;DR: CD177+ neutrophils represent functionally activated population and play a protective role in IBD through increased bactericidal activity and IL-22 production and Targeting CD177+Neutrophils may be beneficial for treatment of IBD.

TL;DR: Serological biomarkers have been demonstrated to be a series of rapid, non-invasive approaches for assessments of early diagnosis, disease activity and prognosis for IBD and have limited values in making initially definite diagnosis for I BD.

TL;DR: It is found that anti-TNF-α therapy significantly downregulated infiltration of neutrophils in inflamed mucosa of IBD patients, indicating that TNF- α plays a critical role in the induction of mucosal inflammatory response, and that blockade of T NF-α modulates intestinal homeostasis through balancing immune responses of neutophils.

TL;DR: The concentrations of LPS and BG were demonstrated to be significantly downregulated in the sera of A-CD patients 12 weeks after IFX treatment, suggesting that blockade of TNF could inhibit bacterial endotoxin absorption, partially through improving intestinal mucosal barrier.

TL;DR: TRIM21 plays a protective role in mucosal inflammation through inhibiting TH1 and TH17 cell differentiation and might serve as a potential therapeutic target for the treatment of IBDs.